Biocrine AB
Records under this name other than the patents Biocrine AB holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 17 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,381,523 | Methods for identifying compounds for treating diabetes mellitus Term ended Term ended May 6, 2025 · From the USPTO record | Term ended | Term ended May 6, 2025 | From the USPTO record |
| US 8,507,444 | ApoIII and the Treatment and Diagnosis of Diabetes Term ended Term ended Feb 5, 2025 · High confidence | Term ended | Term ended Feb 5, 2025 | High confidence |
| US 8,030,288 | Methods for Identifying Compounds for the Treatment of Type 1 Diabetes Term ended Term ended Jan 15, 2025 · High confidence | Term ended | Term ended Jan 15, 2025 | High confidence |
| US 8,021,853 | Inhibition of the β3 subunit of L-type Ca2+ channels Term ended Term ended Jun 21, 2024 · From the USPTO record | Term ended | Term ended Jun 21, 2024 | From the USPTO record |
| US 8,084,439 | Methods for identifying compounds for the treatment of type 1 diabetes Term ended Ended no later than Apr 29, 2024 · From the USPTO record | Term ended | Ended no later than Apr 29, 2024 | From the USPTO record |
| US 9,169,484 | Apoiii and the Treatment and Diagnosis of Diabetes Formerly held Term ended Term ended Apr 29, 2024 · High confidence | Term ended | Term ended Apr 29, 2024 | High confidence |
| US 10,060,935 | ApoIII and the Treatment and Diagnosis of Diabetes Term ended Term ended Apr 29, 2024 · High confidence | Term ended | Term ended Apr 29, 2024 | High confidence |
| US 7,855,049 | Inositol pyrophosphates determine exocytotic capacity Lapsed on the fee record Ended Dec 21, 2022 · From the USPTO record | Lapsed on the fee record | Ended Dec 21, 2022 | From the USPTO record |
| US 9,968,675 | Methods for treating and/or limiting development of diabetes in subjects with amyotrophic lateral sclerosis Lapsed on the fee record Ended May 15, 2022 · From the USPTO record | Lapsed on the fee record | Ended May 15, 2022 | From the USPTO record |
| US 8,716,241 | ApoIII and the Treatment and Diagnosis of Diabetes Lapsed on the fee record Ended May 6, 2022 · High confidence | Lapsed on the fee record | Ended May 6, 2022 | High confidence |